1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Strides Readies SteriScience For Injectables Push

Strikes New Joint Ventures For Carbapenems With Brooks Labs

 
• By Vibha Ravi

Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.

World environment day concept: Two human hands holding big and small trees on blurred farming background
With Stelis Set For Growth, Strides Forms New Company • Source: Shutterstock

India's Strides Pharma Science Limited is expanding its injectables portfolio through a new company, SteriScience Pharma Pvt. Ltd., which will only develop and market synthetic injectables, while manufacturing will be undertaken at third party sites, including at facilities owned by Stelis BioPharma Pvt. Ltd.

Strides will have a 54% stake in SteriScience, with the remaining 46% to be held by Strides’ promoter group led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Teva’s Ratiopharm Bags Rights In Germany To Formycon’s Stelara Biosimilar

 
• By Dean Rudge

Teva’s subsidiary in Germany plans to begin rolling out a biosimilar to Stelara in the third quarter of this year after shaking hands on a distribution agreement with manufacturer Formycon.

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By Dean Rudge

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.

More from Business

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By Dean Rudge

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.